Perfuse Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class therapies to improve retinal blood flow and treat ischemia-driven eye diseases. Its lead candidate, PER-001, is a sustained-release intravitreal therapy designed to address underlying vascular dysfunction in conditions such as glaucoma and diabetic retinopathy.